(NASDAQ: LENZ) Lenz Therapeutics's forecast annual revenue growth rate of 104.92% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 38.7%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.79%.
Lenz Therapeutics's revenue in 2026 is $19,088,000.On average, 9 Wall Street analysts forecast LENZ's revenue for 2026 to be $905,828,443, with the lowest LENZ revenue forecast at $503,927,820, and the highest LENZ revenue forecast at $1,438,915,849. On average, 8 Wall Street analysts forecast LENZ's revenue for 2027 to be $2,702,341,156, with the lowest LENZ revenue forecast at $1,637,765,416, and the highest LENZ revenue forecast at $4,364,531,645.
In 2028, LENZ is forecast to generate $5,302,655,113 in revenue, with the lowest revenue forecast at $3,579,731,163 and the highest revenue forecast at $8,559,749,562.